Impact of miglustat on evolution of atypical presentation of late-infantile-onset Niemann-Pick disease type C with early cognitive impairment, behavioral dysfunction, epilepsy, ophthalmoplegia, and cerebellar involvement: A case report

被引：7

作者：

Cuisset J.-M. ^{[1
,6
]}

Sukno S. ^{[2
]}

Trauffler A. ^{[1
]}

Latour P. ^{[3
]}

Dobbelaere D. ^{[4
]}

Michaud L. ^{[5
]}

Vallée L. ^{[1
]}

机构：

[1] Service de Neuropédiatrie, Hôpital Roger Salengro, Lille

[2] Unité de Neuropédiatrie, Hôpital Saint Vincent, Lille

[3] Service de Neurobiologie, CHU de Lyon-GH Est, Bron

[4] Centre de Reference de Lille des Maladies Hereditaires du Metabolisme, Hôpital Jeanne de Flandre, Lille

[5] Service de Gastropédiatrie, Hôpital Jeanne de Flandre, Lille

[6] Hôpital Roger Salengro, CHRU, Boulevard du Pr Jules Leclercq, Lille, Cedex

来源：

Journal of Medical Case Reports | / 10卷 / 1期

关键词：

Cognition; Epilepsy; Late-infantile; Miglustat; Niemann-pick disease type C;

D O I：

10.1186/s13256-016-1038-9

中图分类号：

学科分类号：

摘要：

Background: Niemann-Pick disease type C is a rare inherited neurodegenerative disease involving impaired intracellular lipid trafficking and accumulation of glycolipids in various tissues, including the brain. Miglustat, a reversible inhibitor of glucosylceramide synthase, has been shown to be effective in the treatment of progressive neurological manifestations in pediatric and adult patients with Niemann-Pick disease type C, and has been used in that indication in Europe since 2010. Case presentation: We describe the case of a 16-year-old white French boy with late-infantile-onset Niemann-Pick disease type C who had the unusual presentation of early-onset behavioral disturbance and learning difficulties (aged 5) alongside epileptic seizures. Over time he developed characteristic, progressive vertical ophthalmoplegia, ataxic gait, and cerebellar syndrome; at age 10 he was diagnosed as having Niemann-Pick disease type C based on filipin staining and genetic analysis (heterozygous I1061T/R934X NPC1 mutations). He was commenced on miglustat therapy aged 11 and over the course of approximately 3 years he showed a global improvement as well as improved cognitive and ambulatory function. During this period he remained seizure free on antiepileptic therapy, using valproate and lamotrigine. Conclusions: Miglustat improved the neurological status of our patient, including seizure control. Based on our findings in this patient and previous published data, we discuss the importance of effective seizure control in neurological improvement in Niemann-Pick disease type C, and the relevance of cerebellar involvement as a possible link between these clinical phenomena. Thus the therapeutic efficacy of miglustat could be hypothesized as a substrate reduction effect on Purkinje cells. © 2016 The Author(s).

引用

共 15 条

[1] Patterson M.C., Hendriksz C.J., Walterfang M., Sedel F., Vanier M.T., Wijburg F., Recommendations for the diagnosis and management of Niemann-Pick disease type C: An update, Mol Genet Metab, 106, pp. 330-344, (2012)
[2] Vanier M.T., Niemann-Pick disease type C, Orphanet J Rare Dis, 5, (2010)
[3] Wraith J.E., Guffon N., Rohrbach M., Hwu W.L., Korenke G.C., Bembi B., Luzy C., Giorgino R., Sedel F., Natural history of Niemann-Pick disease type C in a multicentre observational retrospective cohort study, Mol Genet Metab, 98, pp. 250-254, (2009)
[4] Sevin C., Lesca G., Baumann N., Millat G., Lyon-Caen O., Vanier M.T., Sedel F., The adult form of Niemann-Pick disease type C, Brain, 130, pp. 120-133, (2007)
[5] Skorpen J., Helland I.B., Tennoe B., Use of miglustat in a child with late-infantile-onset Niemann-Pick disease type C and frequent seizures: A case report, J Med Case Rep, 6, (2012)
[6] Iturriaga C., Pineda M., Fernandez-Valero E.M., Vanier M.T., Coll M.J., Niemann-Pick C disease in Spain: Clinical spectrum and development of a disability scale, J Neurol Sci, 249, pp. 1-6, (2006)
[7] Pineda M., Wraith J.E., Mengel E., Sedel F., Hwu W.L., Rohrbach M., Bembi B., Walterfang M., Korenke G.C., Marquardt T., Luzy C., Giorgino R., Patterson M.C., Miglustat in patients with Niemann-Pick disease Type C (NP-C): A multicenter observational retrospective cohort study, Mol Genet Metab, 98, pp. 243-249, (2009)
[8] Miglustat (Zavesca) Summary of Product Characteristics, (2014)
[9] Voikar V., Rauvala H., Ikonen E., Cognitive deficit and development of motor impairment in a mouse model of Niemann-Pick type C disease, Behav Brain Res, 132, pp. 1-10, (2002)
[10] Stein V.M., Crooks A., Ding W., Prociuk M., O'Donnell P., Bryan C., Sikora T., Dingemanse J., Vanier M.T., Walkley S.U., Vite C.H., Miglustat improves Purkinje cell survival and alters microglial phenotype in feline Niemann-Pick disease type C, J Neuropathol Exp Neurol, 71, pp. 434-448, (2012)

← 1 2 →